Diagnostic imaging, outpatient, and cancer care services provider Affidea and Netherlands-based artificial intelligence (AI) firm Aidence have joined forces for lung cancer diagnosis and screening.
Affidea is using Aidence's Veye Chest AI algorithm in a pilot in three countries: Italy, Greece, and Hungary, with the potential to expand to other countries as well. Veye Chest assists and supports radiologists by automatically detecting, classifying, and tracking the growth of pulmonary nodules.
The software identifies pulmonary nodules as small as 3 mm and analyzes roughly 300 images contained in a chest CT. The radiologist receives a 3D representation of the pulmonary nodules and the software provides insight into location, volume, and growth rate. Veye Chest has received the CE Mark and can be used as a second or concurrent reader.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnieeurope.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
